RxDoctor Payments Data

Jessica Strzynski, NP

Family · Freeland, MINPI 1689257784

Payments from drug & device makers

$1,854in general payments, 2019–2025

Across 97 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$358
  • AbbVie$333
  • Novo Nordisk$254
  • Lilly USA, LLC$235
  • Boehringer Ingelheim$141
  • Exact Sciences$88
  • plus $446 from 15 others

What the payments were for

  • Food & beverage$1,854100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,854 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$18,831
Medicare patients
75
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide39$77,724
OzempicSemaglutide60$67,820
EliquisApixaban41$50,358
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$43,339
FarxigaDapagliflozin Propanediol31$40,193
RybelsusSemaglutide22$36,339
JardianceEmpagliflozin19$31,116
MounjaroTirzepatide25$26,046
MyrbetriqMirabegron22$19,583
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$11,094
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$4,450
Humalog Kwikpen U-100Insulin Lispro17$4,273
Atorvastatin Calcium265$3,753
Albuterol Sulfate HfaAlbuterol Sulfate77$2,883
Levothyroxine Sodium195$2,811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$254$104,15882 claims
Lilly USA, LLCTrulicity, Mounjaro$235$103,77064 claims
AstraZenecaFarxiga, Breztri Aerosphere$358$51,28746 claims
PfizerEliquis$72$50,35841 claims
GSKTrelegy Ellipta$62$43,33946 claims
Boehringer IngelheimJardiance$141$31,11619 claims
Astellas Pharma US IncMyrbetriq$36$19,58322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.

Other family in Freeland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →